Theratechnologies Inc T.TH

RE:RE:THTX start commenting

[scarlet1967]

Because his suggestion starting from scratch manufacturing a new PDC with more stable cleavable linker and more potent cytokines doesn't solve the issue and it's not feasible. They don't have resources to start over and if so the sort1 technology is based on over expressed sortilin and transponders responsible for the efflux on cancer cells versus healthy cells which means more internalized PDC in cancer cells staying in the cell resulting in high intra cellular concentrations but at the same time the new PDC with extended half time internalizes in healthy cells less concentration but less efflux net result still a potential concentration level resulting in toxicity. That's why they did the micro array tests to measure the precedence of sortililn in various cancers because it all depends on the ratio of sortilin expression between cancer cells and healthy cells that's why I want to know the rational behind lower and more frequent dosing! Why it can increase the effectiveness and yet acceptable toxicity. So yes a new PDC staying longer in the plasma and more potent war head can increases the effectiveness but it also can cause more severe adverse effects.

realitycheck4u wrote: ".....and or the value of the R&D.".

R&D is only going to be given vale if they spell it all out - which I seriously have my doubts about.  They need to CLEARLY ARTICULATE every single possible concern on what they learned, what it means, what their changes COUKd mean and answer CLEARLY every single question as to why they are or why they are not moving forward in the approach outlined by JFM. 

 

scarlet1967 wrote:

 

 

 

 

 

It seems that they have filled that position as the posting is removed from LinkedIn and their website, also in January this year they hired a legal/medical advisor! As for preclinical projects I believe there are some ongoing studies in collaboration with UQAM, CQDM and Canadian cancer society which was funded in July 2022.

Is THTX and their partners all looking for people for the preclinical studies? Is the last global clinical… posting/ recruit was entirely/only for preclinical studies?

I don’t believe so because most if not all their preclinical studies are run by UQAM who is also looking for research assistant under supervision of very well merited researchers “ principal investigator, senior research assistant”. Why adding research folks to the payroll for a cash strapped company which is planning/prioritizing  profitability? 

Again THTX what are you up to? Let us know in timely manner as excising shareholders won’t like to be kept in the dark for too long especially after all these turns and twists in your R&D projects and current valuation which is a nightmare.

Any potential future retail investors will not get involved unless there is clear picture of what the company is up to even at these low prices. Decent frequent information sharing is a must to do for this ignored company despite $80 million sales and anticipated double digits sale growth. Are the R&D projects and all the current employees with expertise in hepatology/oncology a value lost or value added assets? What’s the process and why? What’s the progress? Bear or bull market you will be valued based on commercial success and or the value of the R&D. As per commercial success the numbers will say it all but the R&D projects need rationalized and convincing explanations of theirs achievable potentials, scientifically and financially. You let the market know and let it decide the probability of success stay quite the focus will be on the probability of failure. 

 

https://www.theratech.com/news-releases/news-release-details/cqdm-quebec-breast-cancer-foundation-and-theratechnologies-fund

 

Theratechnologies Inc. hiring Chef de l’assurance de la qualit clinique mondiale | Manager, Global Clinical Quality Assurance in Montreal, Quebec, Canada | LinkedIn

Theratechnologies Inc. hiring Chef de l’assurance de la qualit clinique mondiale | Manager, Global Clinical Quality Assurance in Montreal, Quebec, Canada | LinkedIn

https://www.linkedin.com/in/genevi%C3%A8ve-lefebvre-aa0009116

 

“Legal Advisor, Medical Affairs

 Theratechnologies Inc.

 Jan 2023 - Present • 2 months

 Montreal, Quebec, Canada Assist the legal affairs team in the review and drafting of commercial and medical contracts.”

 

Universit du Qubec Montral hiring Assitant / Associ de recherche in Montreal, Quebec, Canada

Universit du Qubec Montral hiring Assitant / Associ de recherche in Montreal, Quebec, Canada

 

“Our molecular oncology research laboratory is interested in the development and characterization of a new therapeutic approach against cancer.

 This project is carried out in collaboration with Theratechnologies Inc., a biopharmaceutical company specializing in the marketing and development of drugs that meet unmet needs and is jointly funded by the Consortium Qubcois pour la Dcouverte du Mdicament (CQDM) and the Canadian Cancer Society  .

 Job Description :

 The Research Assistant/Associate will work under the supervision of the Principal Investigator or a Senior Research Associate.  The candidate will perform various scientific and administrative tasks.

 Responsibilities:

 -Have excellent skills in cell culture, microscopy, immunofluorescence, cell and molecular biology (RNA and protein extraction, RT-PCR,

 qPCR, Western-type immunoblotting), cytotoxicity and cell proliferation assays, flow cytometry, manipulation of radioisotopes;

 -Have proven experience in pharmacology and development of ligand binding and internalization assays;

 -Compile, analyze and interpret its results;

 -Maintain an up-to-date laboratory notebook and follow standard operating procedures;

 -Participate in the tasks necessary for the proper functioning of the laboratory.

 

Requirements:

 -University degree (M.Sc., Ph.D.) in biomedical sciences, cell biology, biology, biochemistry, pharmacology or in a related field;

 -Experience in a pharmaceutical environment would be an asset;

 - Ability to organize and document (literature review)

 -Knowledge of Word, Excel, Power Point, and

 GraphPad Prism.

 Personal qualities:

 -Positive, enthusiastic personality,

 

Submission of applications:

 Interested candidates should send their CV, a brief cover letter, and the contact details of

 2-3 people referred by email to Borhane

 Annabi, principal researcher ([e-mail]).

 PS: We thank all applicants for their interest.  Only the people selected for an interview will be contacted.  UQAM subscribes to employment equity.”